ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.

Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the findings from the prospective, multi-center CardiAMP-HF trial (NCT02438306), investigating autologous cell therapy with the CardiAMP system (BioCardia, Inc.) compared to sham control treatment in HFrEF patients. The primary outcome measure was a composite endpoint of all-cause death, non-fatal major adverse cardiac and cerebrovascular events, and change for six-minute walking distance from baseline to month 12.

Findings showed that autologous cell therapy was well-tolerated with trends towards benefit in reduced mortality and MACCE for the treatment group at 2 years, however, the trial did not meet its primary efficacy outcome.

Interview Questions:
1. What is the importance behind the CardiAMP-HF trial?
2. What was the study design, patient population and key findings?
3. Are there plans for a CardiAMP-HF II trial?
4. What were the key take-home messages?

Recorded on-site at ACC in Chicago, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Tom Green, David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.